



Our mission is to detect and treat Alzheimer's disease.

ABOUT US

We are developing a disease-modifying treatment for patients with Alzheimer's disease.

- Our lead product candidate, PTI-125, is a small molecule drug with a novel mechanism of action.
- PTI-125 stabilizes a critical protein in the brain (*our drug does not seek to clear amyloid out of the brain*).
- We are conducting a Phase 2 clinical program with PTI-125 in patients with Alzheimer's disease, with substantial scientific & financial support from the National Institutes of Health (NIH).

We are also developing a diagnostic to detect Alzheimer's disease with a simple blood test.

- In blinded studies our investigational diagnostic, PTI-125Dx, detected >10-fold differences between patients with Alzheimer's and age-matched normal controls or young cognitively intact subjects (N=232).

ABOUT OUR SCIENCE

Our investigational drug for Alzheimer's disease exerts strong anti-neuroinflammatory effects and restores the normal function of key receptors in the brain.

- In animal models of disease, chronic treatment with our drug results in dramatic improvements in brain health, such as improved learning & memory; increased insulin receptor signaling; and decreased neuroinflammation.
- The underlying science for our research program in Alzheimer's is published in prestigious peer-reviewed journals, including *Journal of Neuroscience*, *Neurobiology of Aging*, and *Journal of Biological Chemistry*.
- In addition, our research programs in Alzheimer's disease have been awarded >\$10 million in NIH funding.

For more information please contact Eric Schoen, Chief Financial Officer, eschoen@CassavaSciences.com

KEY FINANCIALS at 3/31/19

- ❖ \$19.1 million, cash & cash equivalents
- ❖ \$5-6.0 million net cash use expected in 2019
- ❖ 17.2 million shares outstanding
- ❖ 9.1 million warrants outstanding
- ❖ \$78.7 million pre-tax NOLs
- ❖ No debt